Reactome | Miller, VA

Schema > Person > Entries

Miller, VA Show undefined attributes

created	[InstanceEdit:6800577] Rothfels, Karen, 2015-09-29
dbId	6800578
displayName	Miller, VA
firstname	Vincent A
initial	VA
publications	[LiteratureReference:9700317] ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression [LiteratureReference:9711845] Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib [LiteratureReference:9702293] Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib [LiteratureReference:9711768] Kinase fusions are frequent in Spitz tumours and spitzoid melanomas [LiteratureReference:8852962] Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma [LiteratureReference:6800632] BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition [LiteratureReference:9634497] HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib [LiteratureReference:9646445] Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer [LiteratureReference:9647018] Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies [LiteratureReference:9831359] Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies [LiteratureReference:9701980] STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion [LiteratureReference:9713415] Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization
schemaClass	Person
surname	Miller

Cite Us!